Chronic d-amphetamine depresses an imaging marker of arachidonic acid metabolism in rat brain

International Journal of Neuropsychopharmacology

Volumn 11, Issue 7, 2008, Pages 957-969

  Bhattacharjee, Abesh K ^a   Chang, Lisa ^a   Chen, Mei ^a   White, Laura ^a   Bell, Jane M ^a   Bazinet, Richard P ^a   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Arachidonic acid; d amphetamine; Dopamine; Quinpirole; SKF 38393

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ARACHIDONIC ACID; BIOLOGICAL MARKER; DEXAMPHETAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; QUINPIROLE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; MALE; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RAT; SECOND MESSENGER; SIGNAL TRANSDUCTION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ARACHIDONIC ACID; AUTORADIOGRAPHY; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSION, CHEMICAL; DEXTROAMPHETAMINE; DOPAMINE AGONISTS; FATTY ACIDS, NONESTERIFIED; HALF-LIFE; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAPERITONEAL; MALE; QUINPIROLE; RATS; RATS, INBRED F344; RECEPTORS, DOPAMINE D2; RECEPTORS, PHOSPHOLIPASE A2; SIGNAL TRANSDUCTION;

EID: 53049084930     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008833     Document Type: Article

References (74)

1. Alexander GE, Crutcher MD (1990). Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends in Neuroscience 13, 266-271.
2. Barnett JV, Segal DS, Kuczenski R (1987). Repeated amphetamine pretreatment alters the responsiveness of striatal dopamine-stimulated adenylate cyclase to amphetamine-induced desensitization. Journal of Pharmacology and Experimental Therapeutics 242, 40-47.
3. 2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology 30, 1064-1075.
4. Basselin M, Villacreses NE, Langenbach R, Ma K, Bell JM, Rapoport SI (2006). Resting and arecoline-stimulated brain metabolism and signaling involving arachidonic acid are altered in the cyclooxygenase-2 knockout mouse. Journal of Neurochemistry 96, 669-679.
5. Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI (2007). Chronic lithium administration attenuates upregulated brain arachidonic acid metabolism in a rat model of neuroinflammation. Journal of Neurochemistry 102, 761-772.
6. Berridge CW, Stalnaker TA (2002). Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex. Synapse 46, 140-149.
7. Bhattacharjee AK, Chang L, Lee HJ, Bazinet RP, Seemann R, Rapoport SI (2005). D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology (Berlin) 180, 735-742.
8. Bhattacharjee AK, Chang L, White L, Bazinet RP, Rapoport SI (2006). D-Amphetamine stimulates D2 dopamine receptor-mediated brain signaling involving arachidonic acid in unanesthetized rats. Journal of Cerebral Blood Flow and Metabolism 26, 1378-1388.
9. Bonhomme N, Cador M, Stinus L, Le Moal M, Spampinato U (1995). Short and long-term changes in dopamine and serotonin receptor binding sites in amphetamine-sensitized rats: a quantitative autoradiographic study. Brain Research 675, 215-223.
10. Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW (1988). Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. Journal of Neurochemistry 50, 346-355.
11. Cai G, Wang HY, Friedman E (2002). Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. Journal of Pharmacology and Experimental Therapeutics 302, 1105-1112.
12. 14C-2- deoxyglucose autoradiography. Journal of Neuroscience 8, 1951-1961.
13. Chang MC, Arai T, Freed LM, Wakabayashi S, Channing MA, Dunn BB, Der MG, Bell JM, Sasaki T, Herscovitch P, Eckelman WC, Rapoport SI (1997). Brain incorporation of [1-11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. Brain Research 755, 74-83.
14. Chen YF, Jin HK, Paul R, Nagahama S (1988). Blunted pressor responsiveness to quinpirole, a specific dopamine D2 receptor agonist, in conscious deoxycorticosterone acetate/NaCl hypertensive rats is related to atrial natriuretic peptide release. Journal of Pharmacology and Experimental Therapeutics 246, 485-492.
15. Chiang YC, Chen PC, Chen JC (2003). D(3) dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Research 972, 159-167.
16. (2+)-dependent translocation domain with homology to PKC and GAP. Cell 65, 1043-1051.
17. Cooper JR, Bloom FE, Roth RH (2003). The Biochemical Basis of Neuropharmacology. Oxford: Oxford University Press.
18. DeGeorge JJ, Nariai T, Yamazaki S, Williams WM, Rapoport SI (1991). Arecoline-stimulated brain incorporation of intravenously administered fatty acids in unanesthetized rats. Journal of Neurochemistry 56, 352-355.
19. 14C]arachidonate to examine regional brain lipid metabolism in unanesthetized rats. Journal of Neuroscience Research 24, 413-423.
20. DeMar Jr. JC, Lee HJ, Ma K, Chang L, Bell JM, Rapoport SI, Bazinet RP (2006). Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats. Biochimica et Biophysica Acta 1761, 1050-1059.
21. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D (2004). Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47 (Suppl. 1), 227-241.
22. Esposito G, Giovacchini G, Der M, Liow JS, Bhattacharjee AK, Ma K, Herscovitch P, Channing M, Eckelman WC, Hallett M, Carson RE, Rapoport SI (2007). Imaging signal transduction via arachidonic acid in the human brain during visual stimulation, by means of positron emission tomography. Neuroimage 34, 1342-1351.
23. Fitzpatrick FA, Soberman R (2001). Regulated formation of eicosanoids. Journal of Clinical Investigation 107, 1347-1351.
24. Folch J, Lees M, Sloane Stanley GH (1957). A simple method for the isolation and purification of total lipides from animal tissues. Journal of Biological Chemistry 226, 497-509.
25. 2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31, 154-162.
26. 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. Journal of Nuclear Medicine 45, 1471-1479.
27. Han DD, Gu HH (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology 6, 6.
28. 3H]arachidonic acid incorporation, a surrogate marker for phospholipase A2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics 296, 1074-1084.
29. Huang YH, Tsai SJ, Wang YC, Yu MF, Yang YC, Sim CB (1997). Differential development of the enhanced metabolic response during amphetamine sensitization. Neuropsychobiology 36, 177-181.
30. Hutchaleelaha A, Sukbuntherng J, Chow HH, Mayersohn M (1994). Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. Drug Metabolism and Disposition 22, 406-411.
31. Jones EG (2002). Thalamic organization and function after Cajal. Progress in Brain Research 136, 333-357.
32. Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998). Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. Journal of Neuroscience 18, 1979-1986.
33. Kimes AS, Sweeney D, Rapoport SI (1985). Brain palmitate incorporation in awake and anesthetized rats. Brain Research 341, 164-170.
34. Kula NS, Baldessarini RJ (1991). Lack of increase in dopamine transporter binding or function in rat brain tissue after treatment with blockers of neuronal uptake of dopamine. Neuropharmacology 30, 89-92.
35. Lago JA, Kosten TR (1994). Stimulant withdrawal. Addiction 89, 1477-1481.
36. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997). Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25, 1-14.
37. Lee HJ, Rao JS, Chang L, Rapoport SI, Bazinet RP (2008). Chronic N-methyl-D-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat. Journal of Lipid Research 49, 162-168.
38. 2-like dopamine receptors in rat brain. Journal of Pharmacology and Experimental Therapeutics 262, 929-935.
39. 2 dopamine receptors in brain with subtype-specific antibodies. Proceedings of the National Academy of Sciences USA 90, 8861-8865.
40. Lillrank SM, Oja SS, Saransaari P, Seppala T (1991). Animal models of amphetamine psychosis: neurotransmitter release from rat brain slices. International Journal of Neuroscience 60, 1-15.
41. Lopez J, Lopez V, Rojas D, Carrasco X, Rothhammer P, Garcia R, Rothhammer F, Aboitiz F (2004). Effect of psychostimulants on distinct attentional parameters in attentional deficit/hyperactivity disorder. Biological Research 37, 461-468.
42. Lu W, Wolf ME (1997). Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration. Brain Research. Molecular Brain Research 49, 137-148.
43. Lynch MA, Leonard BE (1978). Effect of chronic amphetamine administration on the behaviour of rats in the open field apparatus: reversal of post-withdrawal depression by two antidepressants. Journal of Pharmacy and Pharmacology 30, 798-799.
44. Makrides M, Neumann MA, Byard RW, Simmer K, Gibson RA (1994). Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. American Journal of Clinical Nutrition 60, 189-194.
45. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 303, 791-804.
46. Miller HH, Shore PA, Clarke DE (1980). In vivo monoamine oxidase inhibition by d-amphetamine. Biochemical Pharmacology 29, 1347-1354.
47. Mintz M, Gordon I, Roz N, Rehavi M (1994). The effect of repeated amphetamine treatment on striatal DA transporter and rotation in rats. Brain Research 668, 239-242.
48. Neve KA, Seamans JK, Trantham-Davidson H (2004). Dopamine receptor signaling. Journal of Receptor and Signal Transduction Research 24, 165-205.
49. 2+-mobilizing agent. British Journal of Pharmacology 124, 1651-1658.
50. Ong WY, Sandhya TL, Horrocks LA, Farooqui AA (1999). Distribution of cytoplasmic phospholipase A2 in the normal rat brain. Journal fur Hirnforschung 39, 391-400.
51. Orzi F, Dow-Edwards D, Jehle J, Kennedy C, Sokoloff L (1983). Comparative effects of acute and chronic administration of amphetamine on local cerebral glucose utilization in the conscious rat. Journal of Cerebral Blood Flow and Metabolism 3, 154-160.
52. Palacios JM, Wiederhold KH (1985). Dopamine D2 receptor agents, but not dopamine D1, modify brain glucose metabolism. Brain Research 327, 390-394.
53. 2 and cyclooxygenase-2 in Rhesus monkey cerebellum. Brain Research. Molecular Brain Research 116, 106-114.
54. Paulson PE, Camp DM, Robinson TE (1991). Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology (Berlin) 103, 480-492.
55. Paxinos G, Watson C (1987). The Rat Brain in Stereotaxic Coordinates. New York: Academic Press.
56. Persico AM, Schindler CW, O'Hara BF, Brannock MT, Uhl GR (1993). Brain transcription factor expression: effects of acute and chronic amphetamine and injection stress. Brain Research. Molecular Brain Research 20, 91-100.
57. Rao JS, Ertley RN, Rapoport SI, Bazinet RP, Lee HJ (2007). Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. Journal of Neurochemistry 102, 1918-1927.
58. Rapoport SI (1995). Docosahexaenoate turnover in brain phospholipids. Journal of Neurochemistry 65, 1903-1905.
59. Rapoport SI (2001). In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. Journal of Molecular Neuroscirnce 16, 243-261 (discussion 279-284).
60. Rapoport SI, Bosetti F (2002). Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Archives of General Psychiatry 59, 592-596.
61. Rapoport SI, Chang MC, Spector AA (2001). Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. Journal of Lipid Research 42, 678-685.
62. Robertson HA (1986). Cerebral decortication reverses the effect of amphetamine on striatal D2 dopamine binding site density. Neuroscience Letters 72, 325-329.
63. Robinson PJ, Noronha J, DeGeorge JJ, Freed LM, Nariai T, Rapoport SI (1992). A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Research. Brain Research Reviews 17, 187-214.
64. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Research 396, 157-198.
65. Segal DS, Weinberger SB, Cahill J, McCunney SJ (1980). Multiple daily amphetamine administration: behavioral and neurochemical alterations. Science 207, 905-907.
66. Skipski VP, Good JJ, Barclay M, Reggio RB (1968). Quantitative analysis of simple lipid classes by thin-layer chromatography. Biochimica et Biophysica Acta 152, 10-19.
67. Sokoloff L (1999). Energetics of functional activation in neural tissues. Neurochemical Research 24, 321-329.
68. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. Journal of Neurochemistry 28, 897-916.
69. Tabachnick BG, Fidell LS (2001). Computer Assisted Research Design and Analysis. Boston, MA: Allyn and Bacon.
70. Tomic M, Vukosavic S, Joksimovic J (1997). Acute amphetamine and/or phencyclidine effects on the dopamine receptor specific binding in the rat brain. European Neuropsychopharmacology 7, 295-301.
71. Uretsky NJ, Snodgrass SR (1977). Studies on the mechanism of stimulation of dopamine synthesis by amphetamine in striatal slices. Journal of Pharmacology and Experimental Therapeutics 202, 565-580.
72. 2. Journal of Neurochemistry 64, 2765-2772.
73. Weiss F, Imperato A, Casu MA, Mascia MS, Gessa GL (1997). Opposite effects of stress on dopamine release in the limbic system of drug-naive and chronically amphetamine-treated rats. European Journal of Pharmacology 337, 219-222.
74. White FJ, Kalivas PW (1998). Neuroadaptations involved in amphetamine and cocaine addiction. Drug and Alcohol Dependence 51, 141-153.